Apremilast 20mg

DRUG5 trials

Sponsors

Amgen

Conditions

Plaque-type PsoriasisPsoriasisPsoriatic Arthritis

Phase 2

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

CompletedNCT00773734

AmgenPlaque-type Psoriasis, Psoriasis

Start: 2008-09-01End: 2015-05-20Updated: 2020-05-07

Phase 3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

CompletedNCT01172938

AmgenPsoriatic Arthritis

Start: 2010-06-02End: 2016-10-27Updated: 2020-06-19

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

CompletedNCT01212770

AmgenPsoriatic Arthritis

Start: 2010-09-30End: 2017-02-09Updated: 2020-05-06

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

CompletedNCT01212757

AmgenPsoriatic Arthritis

Start: 2010-09-27End: 2017-01-25Updated: 2020-05-06

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

CompletedNCT01307423

AmgenPsoriatic Arthritis

Start: 2010-12-09End: 2017-08-16Updated: 2022-06-14

Related Papers

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

American Journal of Clinical Dermatology2023-06-1440 citations

Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials.

PubMed2021-12-012 citations

Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients

Lara D. Veeken2021-06-0711 citations

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Arthritis Research & Therapy2019-05-1076 citations

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

RMD Open2018-06-0137 citations

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

Lara D. Veeken2018-02-0998 citations

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).

2016-12-19129 citations

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

The Journal of Rheumatology2016-07-15206 citations

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

2016-01-20193 citations

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

The Journal of Rheumatology2015-01-15133 citations

APR Improves PsA Symptoms Out to Week 104

MD Conference Express2014-12-01

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

2014-03-04302 citations

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.

2013-05-1052 citations

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

2012-06-29191 citations